Better Therapeutics logo

Better TherapeuticsNASDAQ: BTTX

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

17 March 2021

Next earnings report:

22 November 2024

Last dividends:

N/A

Next dividends:

N/A
$4.74 K
-100%vs. 3y high
1%vs. sector
-vs. 3y high
-vs. sector
-100%vs. 3y high
17%vs. sector
-vs. 3y high
-vs. sector

Price

regular market | Tue, 19 Nov 2024 14:30:00 GMT
$0.00$0.00(0.00%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

BTTX Latest News

Click Therapeutics Accelerates Expansion into Obesity and Cardiometabolic Disease With Acquisition of the Assets of Better Therapeutics, Inc.
businesswire.com22 May 2024 Sentiment: POSITIVE

NEW YORK--(BUSINESS WIRE)--Click Therapeutics Accelerates Expansion into Obesity and Cardiometabolic Disease With Acquisition of the Assets of Better Therapeutics, Inc.

Better Therapeutics' (BTTX) CBT Gains FDA's Breakthrough Status
Zacks Investment Research22 February 2024 Sentiment: POSITIVE

Better Therapeutics' (BTTX) novel CBT platform attains the FDA's breakthrough device designation to improve patient care in the treatment of liver and metabolic diseases.

Better Therapeutics, Inc. (BTTX) Q2 2023 Earnings Call Transcript
Seeking Alpha09 August 2023 Sentiment: POSITIVE

Better Therapeutics, Inc. (NASDAQ:BTTX ) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants Mark Heinen - Chief Financial Officer Frank Karbe - President and CEO Diane Gomez - Chief Commercial Officer Mark Berman - Chief Medical Officer Conference Call Participants Thomas Flaten - Lake Street Capital Markets Keay Nakae - Chardan Rahul Rakhit - LifeSci Capital Operator Good day and thank you for standing by, and welcome to the Better Therapeutics' Second Quarter 2023 Update Call. At this time all participants are in a listen-only mode.

Better Therapeutics to Release Second Quarter 2023 Financial Results and Provide Business Update on August 09, 2023
Business Wire02 August 2023 Sentiment: POSITIVE

SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX #digitalhealth--Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics to treat cardiometabolic diseases, today announced it will release its second quarter 2023 financial results after the market closes on Wednesday, August 09, 2023. Management will host a conference call and webcast to provide a business update at 4:30 p.m. ET / 1:30 p.m. PT on Wednesday, August 09, 2023. To access the conference call, please register at: https://re.

Why Is Better Therapeutics (BTTX) Stock Up 39% Today?
InvestorPlace11 July 2023 Sentiment: POSITIVE

Better Therapeutics (NASDAQ: BTTX ) stock is taking off on Tuesday as investors react to approval from the FDA for a Type 2 diabetes treatment. This covers AspyreRx, which is a prescription-only digital therapeutic treatment for patients 18 and older with Type 2 diabetes.

Better Therapeutics, Inc. (BTTX) Q1 2023 Earnings Call Transcript
Seeking Alpha14 May 2023 Sentiment: POSITIVE

Better Therapeutics, Inc. (NASDAQ:BTTX ) Q1 2023 Earnings Conference Call May 11, 2023 8:30 AM ET Company Participants Mark Heinen - CFO Frank Karbe - President and CEO Diane Gomez - Chief Commercial Officer Mark Berman - Chief Medical Officer Conference Call Participants Thomas Flaten - Lake Street Capital Markets Lucas Romanski - TD Cowen Keay Nakae - Chardan Keay Rahul Rakhit - LifeSci Capital Operator Good morning and thank you for standing by, and welcome to the Better Therapeutics' First Quarter 2023 Conference Call. At this time all participants are in a listen-only mode.

Better Therapeutics, Inc. (BTTX) Moves to Buy: Rationale Behind the Upgrade
Zacks Investment Research06 April 2023 Sentiment: POSITIVE

Better Therapeutics, Inc. (BTTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

What type of business is Better Therapeutics?

Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company's lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. It also develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions. In addition, the company's clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic kidney disease. Its product pipeline also includes BT-002, which intends glycemic control for hypertension; BT-003 to reduce LDL cholesterol in patients with hyperlipidemia; and BT-004, which intends to explore the impact of treatment on liver health in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease. The company was founded in 2015 and is headquartered in San Francisco, California.

What sector is Better Therapeutics in?

Better Therapeutics is in the Healthcare sector

What industry is Better Therapeutics in?

Better Therapeutics is in the Biotechnology industry

What country is Better Therapeutics from?

Better Therapeutics is headquartered in United States

When did Better Therapeutics go public?

Better Therapeutics initial public offering (IPO) was on 17 March 2021

What is Better Therapeutics website?

https://www.bettertx.com

Is Better Therapeutics in the S&P 500?

No, Better Therapeutics is not included in the S&P 500 index

Is Better Therapeutics in the NASDAQ 100?

No, Better Therapeutics is not included in the NASDAQ 100 index

Is Better Therapeutics in the Dow Jones?

No, Better Therapeutics is not included in the Dow Jones index

When was Better Therapeutics the previous earnings report?

No data

When does Better Therapeutics earnings report?

The next expected earnings date for Better Therapeutics is 22 November 2024